Rheumatology Vol. II: Systemic Autoimmune and Connective Tissue Disease
Three topics, 36 cases — choose one below to browse its cases.
Autologous stem-cell transplant eligibility and digital-ulcer therapy selection in systemic sclerosis, B-cell agent choice in Sjögren's disease, steroid-sparing agent selection across the myositis spectrum, and treatment timing in mixed and undifferentiated connective tissue disease
Biologic selection (anifrolumab vs. belimumab vs. B-cell agents) for non-renal and cutaneous SLE, treatment adjustment across pregnancy and pregnancy planning, and management of major complications including neuropsychiatric lupus, lupus vasculitis, and refractory thrombocytopenia
Biologic and steroid-sparing therapy selection in giant cell arteritis (including relapse-on-treatment and asymptomatic large-vessel disease), Takayasu arteritis, and ANCA-associated and other vasculitides, weighing evidence borrowed across trials, timepoints, and related diseases